Amy D Nguyen

List of Publications by Year
in descending order

49 papers	1,328 citations	394421 19 h-index	361022 35 g-index
50 all docs	50 docs citations	50 times ranked	1995 citing authors

#	Article	IF	Citations
1	Agency and the telephone: Patient contributions to the clinical and interactional agendas in telehealth consultations. Patient Education and Counseling, 2022, 105, 2074-2080.	2.2	6
2	How will telehealth change primary care in Australia?. BJGP Open, 2022, 6, BJGPO.2021.0186.	1.8	4
3	The use and predictive performance of the Peninsula Health Falls Risk Assessment Tool (PH-FRAT) in 25 residential aged care facilities: a retrospective cohort study using routinely collected data. BMC Geriatrics, 2022, 22, 271.	2.7	2
4	Epidemiology of falls in 25 Australian residential aged care facilities: a retrospective longitudinal cohort study using routinely collected data. International Journal for Quality in Health Care, 2022, 34, .	1.8	3
5	Out-of-pocket spending among a cohort of Australians living with gout. International Journal of Rheumatic Diseases, 2021, 24, 327-334.	1.9	7
6	Co-designing a dashboard of predictive analytics and decision support to drive care quality and client outcomes in aged care: a mixed-method study protocol. BMJ Open, 2021, 11, e048657.	1.9	10
7	Communicating deprescribing decisions made in hospital with general practitioners in the community. Internal Medicine Journal, 2021, 51, 1473-1478.	0.8	4
8	Expanding the role of Australian community dietitians in gout management. International Journal of Rheumatic Diseases, 2021, 24, 1402-1408.	1.9	1
9	Reducing antibiotic prescribing using nudges: A systematic review of interventions in primary care. Infection, Disease and Health, 2021, 26, S11.	1.1	1
10	Experiences of telehealth in general practice in Australia: research protocol for a mixed methods study. BJGP Open, 2021, , BJGPO.2021.0187.	1.8	6
11	The co-design of timely and meaningful information needed to enhance social participation in community aged care services: Think tank proceedings. Australasian Journal on Ageing, 2020, 39, e162-e167.	0.9	4
12	A profile of health status and demographics of aged care facility residents with gout. Australasian Journal on Ageing, 2020, 39, e153-e161.	0.9	6
13	Australian patient perspectives on the impact of gout. International Journal of Rheumatic Diseases, 2020, 23, 1372-1378.	1.9	7
14	Neuropeptide Y Regulation of Energy Partitioning and Bone Mass During Cold Exposure. Calcified Tissue International, 2020, 107, 510-523.	3.1	9
15	Better outcomes for patients with gout. Inflammopharmacology, 2020, 28, 1395-1400.	3.9	8
16	Predictors of Success in Gout Treatment. Journal of Rheumatology, 2020, 47, 313-315.	2.0	2
17	Patients' use of mobile health applications: what general practitioners think. Family Practice, 2019, 36, 214-218.	1.9	38
18	Improving adherence to urate-lowering therapy in people living with gout. International Journal of Rheumatic Diseases, 2019, 22, 542-544.	1.9	3

#	Article	IF	Citations
19	At the grassroots of home and community-based aged care: strategies for successful consumer engagement. BMJ Open, 2019, 9, e028754.	1.9	2
20	Delivering the right information to the right person at the right time to facilitate deprescribing in hospital: a mixed methods multisite study to inform decision support design in Australia. BMJ Open, 2019, 9, e030950.	1.9	10
21	Uncoupling protein-1 is protective of bone mass under mild cold stress conditions. Bone, 2018, 106, 167-178.	2.9	22
22	Diet-induced obesity suppresses cortical bone accrual by a neuropeptide Y-dependent mechanism. International Journal of Obesity, 2018, 42, 1925-1938.	3.4	7
23	Imaging of non‑accidental injury; what is clinical best practice?. Journal of Medical Radiation Sciences, 2018, 65, 123-130.	1.5	19
24	Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Family Practice, 2018, 19, 54.	2.9	13
25	mHealth App Patient Testing and Review of Educational Materials Designed for Self-Management of Gout Patients: Descriptive Qualitative Studies. JMIR MHealth and UHealth, 2018, 6, e182.	3.7	12
26	Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. BMJ Open, 2017, 7, e017281.	1.9	9
27	Mobile applications to enhance self-management of gout. International Journal of Medical Informatics, 2016, 94, 67-74.	3.3	33
28	Intermittent Moderate Energy Restriction Improves Weight Loss Efficiency in Diet-Induced Obese Mice. PLoS ONE, 2016, 11, e0145157.	2.5	11
29	A User-Centred Approach to Designing an eTool for Gout Management. Studies in Health Technology and Informatics, 2016, 227, 28-33.	0.3	4
30	NPY signalling in early osteoblasts controls glucose homeostasis. Molecular Metabolism, 2015, 4, 164-174.	6.5	39
31	The neuropeptide Y-ergic system: potential therapeutic target against bone loss with obesity treatments. Expert Review of Endocrinology and Metabolism, 2015, 10, 177-191.	2.4	2
32	Double deletion of orexigenic neuropeptide Y and dynorphin results in paradoxical obesity in mice. Neuropeptides, 2014, 48, 143-151.	2.2	4
33	Neuropeptide Y is a critical modulator of Leptin's regulation of cortical bone. Journal of Bone and Mineral Research, 2013, 28, 886-898.	2.8	39
34	Neuropeptide Y mediates the short-term hypometabolic effect of estrogen deficiency in mice. International Journal of Obesity, 2013, 37, 390-398.	3.4	13
35	Neuropeptide Y1 Receptor in Immune Cells Regulates Inflammation and Insulin Resistance Associated With Diet-Induced Obesity. Diabetes, 2012, 61, 3228-3238.	0.6	36
36	Adult-onset PYY overexpression in mice reduces food intake and increases lipogenic capacity. Neuropeptides, 2012, 46, 173-182.	2.2	23

#	Article	IF	Citations
37	Y1 and Y5 Receptors Are Both Required for the Regulation of Food Intake and Energy Homeostasis in Mice. PLoS ONE, 2012, 7, e40191.	2.5	74
38	NPY modulates PYY function in the regulation of energy balance and glucose homeostasis. Diabetes, Obesity and Metabolism, 2012, 14, 727-736.	4.4	29
39	Macrophage Inhibitory Cytokine 1 (MIC-1/GDF15) Decreases Food Intake, Body Weight and Improves Glucose Tolerance in Mice on Normal & Obesogenic Diets. PLoS ONE, 2012, 7, e34868.	2.5	156
40	Peptide YY Regulates Bone Remodeling in Mice: A Link between Gut and Skeletal Biology. PLoS ONE, 2012, 7, e40038.	2.5	69
41	Osteoblast specific Y1 receptor deletion enhances bone mass. Bone, 2011, 48, 461-467.	2.9	85
42	Neuropeptide Y and peptide YY: important regulators of energy metabolism. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 56-60.	2.3	78
43	Peripheral-Specific Y2 Receptor Knockdown Protects Mice From High-Fat Diet-Induced Obesity. Obesity, 2011, 19, 2137-2148.	3.0	55
44	Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes, Obesity and Metabolism, 2010, 12, 591-603.	4.4	35
45	Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways. Neuropeptides, 2010, 44, 261-268.	2.2	42
46	Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. International Journal of Obesity, 2010, 34, 357-373.	3.4	65
47	Peptide YY Is Critical for Acylethanolamine Receptor Gpr119-Induced Activation of Gastrointestinal Mucosal Responses. Cell Metabolism, 2010, 11, 532-542.	16.2	100
48	NPY Neuron-Specific Y2 Receptors Regulate Adipose Tissue and Trabecular Bone but Not Cortical Bone Homeostasis in Mice. PLoS ONE, 2010, 5, e11361.	2.5	62
49	Critical Role of Arcuate Y4 Receptors and the Melanocortin System in Pancreatic Polypeptide-Induced Reduction in Food Intake in Mice. PLoS ONE, 2009, 4, e8488.	2.5	59